Adalimumab for adult patients with Crohn's disease a review of clinical effectiveness
The objective of this report is to review and summarize the relevant literature regarding the clinical effectiveness of adalimumab [ADA] versus infliximab [IFX] or vedolizumab [VEDO] (an anti-integrin) in adult patients with Crohn's disease
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa, Ont.
Canadian Agency for Drugs and Technologies in Health
2020, May 13, 2020
|
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to review and summarize the relevant literature regarding the clinical effectiveness of adalimumab [ADA] versus infliximab [IFX] or vedolizumab [VEDO] (an anti-integrin) in adult patients with Crohn's disease |
|---|---|
| Physical Description: | 1 PDF file (36 pages) |